Otsuka Signs Three-Year Collaboration with Holmusk to Enhance Digital Health and Data Analytics for Global Behavioral Health Programs
PR90524
PRINCETON, N.J., July 8, 2021 /PRNewswire=KYODO JBN / --
Otsuka Pharmaceutical Development & Commercialization, Inc. ("Otsuka"),
announces today that it has entered a three-year collaboration with Holmusk
Inc. ("Holmusk"), a global data science and digital health company building the
world's largest real-world evidence (RWE) platform for behavioral health.
Together, Otsuka and Holmusk will work to drive a deeper understanding of unmet
patient needs and real-world outcomes by employing proprietary analytics and
artificial intelligence (AI) on multiple real-world data sources. These
insights can have application across Otsuka's portfolio and have the potential
to improve patient lives. The new collaboration, worth up to US$4 million
annually, marks an expansion of the existing relationship that started with an
exploration of real-world outcomes in behavioral health in 2020.
"Holmusk is a global leader in real-world evidence and owns distinctive data
assets for behavioral health. This collaboration strengthens Otsuka's
capabilities in serving people living with complex, chronic diseases," said
Christoph Koenen, MD, executive vice president, and chief medical officer,
Otsuka Pharmaceutical Development & Commercialization, Inc. "This is the next
step in Otsuka's journey to utilize real-world evidence to improve clinical
development with the goal of achieving better patient outcomes. We look forward
to working together."
"We're thrilled to collaborate with Otsuka," said Nawal Roy, Holmusk founder
and CEO. "Their commitment and passion to help patients suffering from poor
behavioral health aligns with our mission. The expertise they provide to guide
these efforts ensure we are targeting the right questions and allow us to get
the most from our digital and analytics assets."
As part of the collaboration, Otsuka's affiliate, Otsuka Pharmaceutical Europe
Limited ("OPEL"), transferred its Otsuka Health Solutions (OHS) digital assets
based in the U.K. to Holmusk. OHS improves mental health services delivery
through predictive analytics.
"Otsuka remains committed to supporting mental health and this collaboration
ensures we are invested in the future success of Holmusk, which will continue
to enhance delivery of care with providers in the UK," said Sahil Kirpekar,
M.D., head of Business Development at Otsuka. Fraser Finance acted as an
advisor to Otsuka to support the transfer of the Otsuka Healthcare Solutions
assets in the UK.
About Otsuka
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the
corporate philosophy: "Otsuka–people creating new products for better health
worldwide." Otsuka researches, develops, manufactures, and markets innovative
products, with a focus on pharmaceutical products to meet unmet medical needs
and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental,
renal and cardiovascular health and has additional research programs in
oncology and on several under-addressed diseases including tuberculosis, a
significant global public health issue. These commitments illustrate how Otsuka
is a "big venture" company at heart, applying a youthful spirit of creativity
in everything it does.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates
include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and
Otsuka America Pharmaceutical, Inc. (OAPI). These two companies' 1,700
employees in the U.S. develop and commercialize medicines in the areas of
mental health, nephrology, and cardiology, using cutting-edge technology to
address unmet healthcare needs.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd.,
which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo,
Japan. The Otsuka group of companies employed 47,000 people worldwide and had
consolidated sales of approximately USD 13.3 billion in 2020.
All Otsuka stories start by taking the road less traveled. Learn more about
Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and
Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is
accessible at www.otsuka.co.jp/en/.
About Holmusk
Holmusk is on a mission to reinvent behavioral health and transform lives with
Real-World Evidence and digital innovation. Headquartered in Singapore and New
York, Holmusk generates evidence and builds digital solutions to advance
behavioral health research, innovation, and care.
NeuroBlu, Holmusk's flagship product, synthesizes Real-World Data (RWD) with
seamless analytic tools, enabling users to create actionable insights that
drive behavioral health transformation. NeuroBlu is powered by an
industry-leading and continually growing behavioral health clinical dataset,
with over 20 years of data on 560,000+ patients and 20+ million encounters.
Holmusk uses advanced proprietary analytics to enrich the data, with Natural
Language Processing and predictive disease models designed specifically for
behavioral health. Holmusk augments its data and analytic offerings with
powerful digital solutions that enhance patient engagement, support disease
self-management, and capture patient-reported outcomes to guide clinical
decisions and analytics. For more information, please visit www.holmusk.com.
Source: Holmusk
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。